Titre (en)
Checkpoint
Istex
Racine
Checkpoint
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration MERS - Checkpoint (Istex)

Index « Titre (en) » - entrée « therapy »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
therapies < therapy < there  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000093 (2015) Rachael S. Felberbaum [États-Unis]The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
000152 (2015) Vitor H. Pomin [Brésil]A Dilemma in the Glycosaminoglycan‐Based Therapy: Synthetic or Naturally Unique Molecules?
000385 (2012) Yonghong Zhang [République populaire de Chine] ; Yali Liu [République populaire de Chine] ; Yan Zhao [République populaire de Chine] ; Lingxian Shi [République populaire de Chine] ; Lina Ma [République populaire de Chine] ; Huiping Yan [République populaire de Chine] ; Hao Wu [République populaire de Chine] ; Lai Wei [République populaire de Chine] ; Tao Dong [Royaume-Uni] ; Xinyue Chen [République populaire de Chine]Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients
000439 (2011) Samer R. Abulateefeh [Royaume-Uni, Jordanie] ; Sebastian G. Spain [Royaume-Uni] ; Jonathan W. Aylott [Royaume-Uni] ; Weng C. Chan [Royaume-Uni] ; Martin C. Garnett [Royaume-Uni] ; Cameron Alexander [Royaume-Uni]Thermoresponsive Polymer Colloids for Drug Delivery and Cancer Therapy
000787 (2008) J. M. Rolland [Australie] ; R. E. O'Hehir [Australie]Latex allergy: a model for therapy
000926 (2007) C. V. Sapan ; H. M. Reisner [États-Unis] ; R. L. Lundblad [États-Unis]Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics
000997 (2006) Jean D. Boyer [États-Unis] ; Sanjeev Kumar [États-Unis] ; Tara Robinson [États-Unis] ; Rose Parkinson [États-Unis] ; Ling Wu [États-Unis] ; Mark Lewis [États-Unis] ; David I. Watkins [États-Unis] ; David B. Weiner [États-Unis]Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T‐cell immune response
000A74 (2005) Lucy M. Carruth [États-Unis] ; M. Christine Zink [États-Unis] ; Patrick M. Tarwater [États-Unis] ; Michael D. Miller [États-Unis] ; Ming Li [États-Unis] ; Laurie A. Queen [États-Unis] ; Joseph L. Mankowski [États-Unis] ; Anding Shen [États-Unis] ; Robert F. Siliciano [États-Unis] ; Janice E. Clements [États-Unis]SIV‐specific T lymphocyte responses in PBMC and lymphoid tissues of SIV‐infected pigtailed macaques during suppressive combination antiretroviral therapy
000A76 (2005) Jay P. Brooks [États-Unis]Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products
000B05 (2005) Kevin J. Harrington [Royaume-Uni] ; Christopher M. Nutting [Royaume-Uni] ; Hardev S. Pandha [Royaume-Uni]Gene therapy for head and neck cancer
000C83 (2003) Nathan SeppaFlawed therapy: Hormone replacement takes more hits
000D61 (2002) Salah-Eddine Stiriba ; Holger Frey [Allemagne] ; Rainer Haag [Allemagne]Dendritic Polymers in Biomedical Applications: From Potential to Clinical Use in Diagnostics and Therapy
000E15 (2001) Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients
000E84 (2001) Flt3-ligand in combination with CD40-ligand gene transfer following radiation-incudible HSV-TK gene therapy improves survival in mice with diffuse hepatocellular carcinoma
000F23 (2001) Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area
001510 (1997) Mj Tong [États-Unis] ; Lm Blatt [États-Unis] ; Jg Mchutchison [États-Unis] ; Rl Co [États-Unis] ; A. Conrad [États-Unis]Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
001863 (1995) David A. Hafler ; Howard L. WeinerImmunologic Mechanisms and Therapy in Multiple Sclerosis

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i -k "therapy" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/Title.i  \
                -Sk "therapy" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Istex
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Title.i
   |clé=    therapy
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021